Safingol

Safingol

SCHEMBL6772

CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 1.00
SPHK1 Q9NYA1 4/20 1.00
LMNA P02545 4/20 1.00
MAPT P10636 4/20 1.00
GMNN O75496 3/20 1.00
POLB P06746 3/20 1.00
BLM P54132 3/20 1.00
CETP P11597 3/20 1.00
UBE2N P61088 3/20 1.00
THPO P40225 2/20 1.00
TP53 P04637 2/20 1.00
CYP1A2 P05177 2/20 1.00
MTOR P42345 1/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP3A4 P08684 1/20 1.00
HTT P42858 1/20 1.00
CSNK1E P49674 1/20 0.54
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
GLA P06280 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1907293 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL18127645 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL7106054 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL8746720 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL1901499 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL3509781 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL13285654 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
Dihydrospingosine SCHEMBL1905632 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL21660227 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN
SCHEMBL21431064 1.00 CYP2D6 (1.00) CYP2D6SPHK1LMNAMAPTGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 12430 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
WO-2025120106-A1 METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AN AVIAN EMBRYO CELLS SUPRÊME (FR) 2025-06-12 WO claimed
EP-4567102-A1 METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AVIAN EMBRYONIC CELLS Suprême (FR) 2025-06-11 EP claimed
EP-4524131-A1 SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH AlonBio Ltd. (IL) 2025-03-19 EP claimed
US-12202803-B2 Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death ALONBIO LTD. (IL) 2025-01-21 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-12109219-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2024-10-08 US claimed
EP-4401780-A1 AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF University of Maryland, College Park (US) 2024-07-24 EP claimed
US-20240066006-A1 Antiviral Compounds and Applications Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-02-29 US claimed
WO-2000000207-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS CHILDREN'S HOSPITAL OF LOS ANGELES (US) 2000-01-06 WO claimed
WO-1999041984-A9 INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) HUTCHINSON FRED CANCER RES (US) 1999-11-04 WO claimed
WO-1999041984-A1 INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) FRED HUTCHINSON CANCER RESEARCH CENTER (US) 1999-08-26 WO claimed
EP-0799035-A4 EMULSION SUITABLE FOR ADMINISTERING A SPHINGOLIPID AND USE THEREOF PHARMACIA & UPJOHN AB (SE) 1999-06-09 EP claimed
EP-0888458-A1 COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS Sloan-Kettering Institute For Cancer Research (US) 1999-01-07 EP claimed
US-5677341-A Emulsion suitable for administering a sphingolipid PHARMACIA & UPJOHN AKTIEBOLAG (SE) 1997-10-14 US claimed
EP-0799035-A1 EMULSION SUITABLE FOR ADMINISTERING A SPHINGOLIPID AND USE THEREOF Pharmacia & Upjohn Aktiebolag (SE) 1997-10-08 EP claimed
WO-1997030174-A1 COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1997-08-21 WO claimed
US-5635536-A Emulsion suitable for administering a sphingolipid PHARMACIA & UPJOHN AKTIEBOLAG (SE) 1997-06-03 US claimed
WO-1996017603-A1 EMULSION SUITABLE FOR ADMINISTERING A SPHINGOLIPID AND USE THEREOF PHARMACIA & UPJOHN AB (SE) 1996-06-13 WO claimed